Welcome to our dedicated page for Edwards Lifesciences news (Ticker: EW), a resource for investors and traders seeking the latest updates and insights on Edwards Lifesciences stock.
Edwards Lifesciences Corporation reports developments in structural heart medical technology, including surgical tissue valves, transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies. Company news commonly covers the SAPIEN TAVR platform, PASCAL transcatheter edge-to-edge repair technology, the EVOQUE transcatheter tricuspid valve replacement system, and RESILIA tissue used in surgical and transcatheter valve innovations.
Recurring updates include quarterly results, clinical-trial data presented at cardiovascular meetings, reimbursement and guideline developments affecting valve procedures, product pipeline commentary, healthcare conference appearances, access initiatives for structural heart treatment, and finance leadership or governance announcements.
Edwards Lifesciences reported Q2 2021 sales of $1.4 billion, a 49% increase year-over-year, with TAVR sales up 52% to $902 million. Adjusted EPS reached $0.64. The company raised its full-year sales guidance to $5.2-$5.4 billion from $4.9-$5.3 billion. Continued advancements in five pivotal trials for TMTT were noted, with a market opportunity projected to triple by 2025. Free cash flow was reported at $457 million. Edwards remains optimistic about long-term growth driven by increasing adoption of its innovative therapies.
Edwards Lifesciences (NYSE: EW) announced positive clinical and economic results from the 3M Transcatheter Aortic Valve Replacement (TAVR) Economic Study and the PARTNER 3 Bicuspid Registry at TVT 2021. The 3M-TAVR study indicated reduced hospitalization costs by $10,843 per patient and cumulative savings of $11,305 within 30 days compared to traditional TAVR. The PARTNER 3 study showed similar clinical outcomes for low-risk patients with bicuspid versus tricuspid aortic valves. Both studies support TAVR's efficiency and highlight its potential to save healthcare costs.
Edwards Lifesciences (NYSE: EW) will announce its operating results for Q2 2021 on July 29, 2021, after market close. A conference call is scheduled for 5:00 p.m. ET the same day to discuss these results. Interested participants can join the call at (877) 704-2848 or (201) 389-0893, with an audio replay available for 72 hours. The call will also be streamed live or archived on the Investor Relations section of the Edwards website.
Edwards Lifesciences announced FDA clearance for its Acumen Hypotension Prediction Index (HPI) software, utilizing the noninvasive Acumen IQ finger cuff. This innovative solution, employing machine learning, alerts clinicians about the risk of hypotension in patients not requiring invasive arterial lines. The Acumen IQ cuff will be integrated with the HemoSphere advanced monitoring system, enabling real-time hemodynamic monitoring and promoting better patient outcomes. The launch reflects Edwards' commitment to enhancing patient care with smart monitoring tools.
Edwards Lifesciences (NYSE: EW) announced positive results from a real-world study on patients with bicuspid aortic stenosis treated with SAPIEN 3 and SAPIEN 3 Ultra TAVR. The one-year data showed low rates of death (4.6%) and stroke (2.0%), comparable to tricuspid valve patients. The study incorporated over 6,000 patients, indicating significant quality of life improvements and minimal paravalvular leak rates. These findings enhance physician confidence in recommending TAVR for younger patients, aligning with recent ACC/AHA guidelines emphasizing shared decision-making.
Edwards Lifesciences (NYSE: EW) announced positive clinical outcomes from its transcatheter mitral and tricuspid valve programs presented at EuroPCR 2021. Key findings include:
- TRISCEND study: 30-day results showed device success of 98% and significant TR reduction.
- CLASP study: 2-year survival rate at 80% with an 85% reduction in heart failure hospitalizations.
- CLASP TR study: 6-months data indicated substantial safety and TR reduction.
- TriBAND study: 30-day outcomes revealed a device success rate of 97% with low mortality at 1.6%.
Both the PASCAL and Cardioband systems hold CE Mark in Europe but are not yet approved in the U.S.
Edwards Lifesciences Corporation (NYSE: EW) held its annual meeting on May 5, 2021, where stockholders voted in favor of all board recommendations. Key outcomes included the election of eight directors for one-year terms, approval of executive compensation, and ratification of the independent accounting firm for fiscal 2021. Additionally, the board authorized an extra $1 billion for share repurchases, complementing the remaining $262 million authorization. Changes in board leadership were noted, including Nicholas J. Valeriani's appointment as chair of the compensation committee and William J. Link's retirement.
Edwards Lifesciences is partnering with Providence and local cities to establish two mass COVID-19 vaccination clinics in Orange County, California. The clinics will be located at Edwards' Santa Ana campus and the Orange County Great Park. The Santa Ana site is now operational while the Irvine site opens on April 26, 2021. The initiative, supported by a $500,000 donation from Edwards, aims to vaccinate up to 4,000 residents daily. Providence has already administered over 256,815 doses and is committed to equitable vaccine distribution in vulnerable communities.
Edwards Lifesciences reported Q1 2021 financial results with sales of $1.2 billion, an 8% year-over-year increase. Diluted EPS was $0.54, surpassing expectations. Notable TAVR sales reached $792 million, growing 7%. The company received approval for pivotal trials in TAVR for moderate AS patients and low surgical risk patients in Japan. Adjusted EPS guidance for 2021 has been raised to $2.07 to $2.27. Despite expected near-term COVID impacts, Edwards forecasts robust growth in structural heart procedures, with a projected global TAVR market exceeding $7 billion by 2024.
Edwards Lifesciences (NYSE: EW) is set to announce its operating results for the quarter ending March 31, 2021, after market close on April 20, 2021. A conference call will be held at 5:30 p.m. ET that day to discuss these results. Investors can participate by calling (877) 704-2848 or (201) 389-0893. An audio replay will be accessible for 72 hours post-call. The call will also be available via a live or archived webcast on their Investor Relations website.